JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258933

Human KMT2C (MLL3) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

KMT2C KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 239 bp insertion in exon6.
1 Images
Sanger Sequencing - Human KMT2C (MLL3) knockout HeLa cell lysate (AB258933)
  • Sanger seq

Unknown

Sanger Sequencing - Human KMT2C (MLL3) knockout HeLa cell lysate (AB258933)

Homozygous : 239 bp insertion in exon6

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 239 bp insertion in exon6.

Disease

Adenocarcinoma

style
left-column

Complementary Products

Primary Antibodies

AB26

Anti-p53 antibody [PAb 240]

KO Validated|Lab Essentials

Western blot - Anti-p53 antibody [PAb 240] (AB26)

  • 4
  • 56
Primary Antibodies

AB231239

Anti-KMT2D / MLL2 antibody

Western blot - Anti-KMT2D / MLL2 antibody (AB231239)

  • 0
  • 0
Primary Antibodies

AB108931

Anti-HAUSP / USP7 antibody [EPR4253]

RabMAb|Recombinant|KO Validated

Western blot - Anti-HAUSP / USP7 antibody [EPR4253] (AB108931)

  • 4
  • 2
Cell Lines & Lysates

AB265223

Human KMT2C (MLL3) knockout HeLa cell line

Sanger Sequencing - Human KMT2C (MLL3) knockout HeLa cell line (AB265223)

  • 0
  • 0
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258933-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human KMT2C knockout HeLa cell lysate", "number":"AB258933-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258933-CMP02", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
KMT2C
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

KMT2C also known as MLL3 is a histone methyltransferase enzyme. Its mass is approximately 553 kDa. This protein exists in various tissues but expresses highly in the brain and bone marrow. It is part of the SET1 family of methyltransferases and plays an important role in modifying chromatin architecture by catalyzing the methylation of histone H3 lysine 4 (H3K4) a modification associated with active transcription.
Biological function summary

KMT2C impacts diverse cellular functions through its participation in the COMPASS-like complex which acetylates histone tails to regulate gene expression. This function is important in controlling genes linked to development and differentiation. KMT2C also supports the maintenance of genomic stability. Mutations in this protein often disrupt important brain and immune processes implicating its importance in physiological conditions.

Pathways

KMT2C plays a vital role in the Wnt and Hedgehog signaling pathways. These pathways regulate embryonic development cell fate decisions and cellular proliferation. Interaction with proteins such as β-catenin and GLI3 links KMT2C with the transcriptional activation of target genes further extending its influence on gene expression regulation and developmental processes.

Mutations or dysregulation of KMT2C are linked to cancers and Kabuki syndrome. In cancers KMT2C often exhibits loss-of-function mutations impacting tumor suppressor capabilities. In Kabuki syndrome alterations in KMT2C disrupt developmental signaling manifesting in intellectual disabilities and characteristic facial features. Interactions with proteins like EZH2 and KDM6A suggest KMT2C's critical involvement in disease pathogenesis and potential pathways for therapeutic intervention.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com